The out-of-pocket (OOP) expenses for care related to breast cancer can be burdensome for survivors. We know little about the kind and amount of OOP for survivors' care, health maintenance and management of side effects. The objective is to report on expenses in 150 participants in the Rural Breast Cancer Survivor Intervention (RBCS), a clinical trial evaluating a psychoeducational quality of life intervention. METHODS: Breast cancer survivors recruited for the trial were 1-3 years post diagnosis, at least 21 years old and residing in rural Florida. OOP data collected at baseline included expenditures for Medical Care (hospital, ER, and doctors' bills, medical supplies, drugs, travel to treatment, physical therapy), Counseling and Health Maintenance (family or individual support, alternative treatments, nutritional counseling, exercise or gym/health club memberships, genetic testing/counseling), Side Effect Management (wigs, prostheses), and Home Maintenance (house cleaning/cooking, additional maintenance or child care). We report mean monthly costs for the period from diagnosis to baseline. RESULTS: Of 150 mostly white women, 91.3% were insured, 30.0% had incomes > $50,000, and 60.7% were >24 months post diagnosis. A total of 94.7% reported OOP spending
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Thomson Reuters, Cambridge , MA, USA, 2 Amgen, Inc, Thousand Oaks, CA, USA, 3 Thomson Reuters, Washington, DC, USA OBJECTIVES: To estimate the cost of illness and assess the primary cost drivers of treating patients with newly diagnosed metastatic colorectal cancer (mCRC) after the introduction of biologic therapies. METHODS: Patients newly diagnosed with mCRC between 2004 and 2008 were identified using a large national claims database of a US commercially insured population. Patients were followed from initial mCRC diagnosis to death, disenrollment, or 7/31/2009, whichever occurred first. mCRC costs were estimated by the cost difference between mCRC patients and their matched non-cancer cohorts. mCRC patients and controls were 1:1 matched on age, gender, geographic region, calendar year of diagnosis, and Deyo-Charlson Comorbidity Index. Both total and component costs (inpatient, emergency room, outpatient, or pharmacy/ biologics) were analyzed. The multivariate, survival-based M1 method was used to estimate costs in order to handle a variable length of follow-up and data censoring issues. RESULTS: A total of 6,746 mCRC patients met all eligibility criteria for the study. They were matched to patients without cancer, resulting in a 98.9% match rate and a final sample of 6,675 mCRC patients were included in this study. Mean (standard deviation) age was 64.1 (13.1) and 62.6 (14.1) for cases and controls, respectively, and 55.5% were males in both cohorts. Compared with matched patients without cancer, total monthly costs were $14,585 higher for mCRC patients, which was mainly driven by higher cost of inpatient ($7,546) and outpatient ($4,197) care, accounting for over 80% of the total health care costs attributable to mCRC. CON-CLUSIONS: The economic burden of mCRC is substantial. Inpatient and outpatient care remain key cost drivers in the medical management of mCRC.
PCN37

BURDEN OF INPATIENT CASES OF ACUTE EXACERBATIONS OF COPD WITH LUNG CANCER IN THE UNITED STATES IN 2006
Perera P 1 , Skrepnek G 2 1 College of Pharmacy, University of Arizona, Tucson, AZ, USA, 2 University of Arizona College of Pharmacy Center for Health Outcomes and PharmacoEconomic Research, Tucson, AZ, USA OBJECTIVES: To determine: 1) hospitalization charges of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) with lung cancer; and 2) the clinical, socio-demographic, and hospital characteristics associated with inpatient charges. METHODS: A retrospective study of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample for 2006. An AECOPD was identified via ICD-9-CM codes in the first three diagnosis positions: 1) 491.2x identifying AECOPD; 2) 490.x-492.x and 494.x-496 identifying COPD with either pneumonia (480.x-486); or a procedure code for mechanical ventilation (93.90, 96.70-96.72 ) in any position. Lung cancer in AECOPD was identified by the ICD-9-CM code 162.x. Discharge records were included if patients ≥40 years. Regression analyses were conducted using generalized linear model with gamma family with charges as the primary outcome. Significance was set a priori at the 0.05 level. RESULTS: A total of 42521 hospital discharges with mean(±SD) hospitalization charge of $33436(±43647) and length of stay of 7.0(±6.8) days. In-hospital mortality was 10.6%. The majority was ≥65 years (73.6%), male (55.2%), had ≥4 comorbidities (62%), with Medicare as the primary payer (75.0%). Among cases that reported race, 84.6% were white. Age <65 year, black race (compared to white), hospitals with larger bed size, urban hospitals (compared to rural), in-hospital mortality, greater number of comorbidities, and presence of specific cormorbidities such as congestive heart failure, arrhythmias, pulmonary circulation disorders, cerebrovascular disease, and weight loss were significantly associated (p≤0.01) with increased hospitalization charges. The Midwest and South (compared to Northeast) regions, Medicaid (compared to Medicare) and comorbidities such as depression and ischemic heart disease were significantly (p≤0.05) associated with decreased charges. CONCLUSIONS: The inpatient burden of AECOPD with lung cancer is substantial with a number of socio-demographic, hospital and clinical characteristics, particularly other comorbidities prevalent in COPD, associated with hospitalization charges.
PCN39 MORTALITY COSTS FROM GENITAL CANCERS IN MEN-UNITED STATES, 2004
Li C, Ekwueme DU, Rim SH, Tangka FK Center for Disease Control and Prevention, Atlanta, GA, USA OBJECTIVES: To estimate mortality costs measured as years of potential life lost (YPLL) and productivity loss in 2004 due to deaths from all cancers and from genital cancers specifically among men in the US. METHODS: To estimate YPLL, we used 2004 national mortality data and life tables by multiplying the number of deaths and average remaining life years for specific age groups. To estimate lifetime productivity loss, we applied the human capital approach by multiplying the number of deaths by the expected value of decedents' future earnings estimated using the American Time Use Survey, accounting for both the market value and the imputed value of housekeeping services. We calculated results for age and racial/ethnic groups and for four categories of male genital cancer (prostate, testicular, penile, and other). RESULTS: In 2004, deaths from male genital cancers accounted for 309,921 YPLL, 6.8% of the estimated 4.5 million YPLL attributable to deaths from all cancers among US men. Prostate cancer accounted for 94.2% of the YPLL, and testicular cancer accounted for the highest average number of YPLL per death (37.9). Non-Hispanic whites accounted for 75.9% of the YPLL from male genital cancer deaths, and non-Hispanic blacks had the highest YPLL rate (297.0/100,000 men). Overall, genital cancers had the largest relative contribution to YPLL among men aged ≥50 years compared to other age groups. In 2004, the estimated lifetime productivity loss due to deaths from male genital cancers was $5.4 billion, 5.7% of the estimated $97.9 billion loss due to deaths from all cancers among US men. CONCLUSIONS: Male genital cancers impose a considerable health and economic burden in terms of premature deaths and productivity loss in the United States.
PCN40 RETROSPECTIVE COST AND OUTCOME ANALYSIS OF BREAST CANCER PATIENTS TREATED IN A BRAZILIAN OUTPATIENT CANCER CENTER (OCC)
Teich N 1 , Souza CPR 1 , Teich V 1 , Cintra M 1 , Musacchio JG 2 , Vieira FM 1 1 MedInsight, Rio de Janeiro, Rio de Janeiro, Brazil, 2 COI-Clinicas Oncológicas Integradas, Rio de Janeiro, Rio de Janeiro, Brazil OBJECTIVES: To determine the cost and outcome related to breast cancer patients treated in a Brazilian OCC in Rio de Janeiro, Brazil. METHODS: This is a retrospective study of women with breast cancer treated at a private practice OCC in Rio de Janeiro, Brazil. All the patients were covered by Amil, a Brazilian HMO. Direct costs (DC) of 199 patients diagnosed since 2002 and followed to the end of 2009 were analyzed and correlated to clinical stage. We used Kaplan-Meier method to analyse patients' outcome. RESULTS: Forty-eight percent of women were diagnosed in stage I, 34% patients in stage II, and only 2.5% were diagnosed in stage IV, similar numbers to those seen in developed countries. The average DC of their medical care per patient was 21,658.94 USD for stage I compared to 48,295.29 USD for stage II, and were 63,662.06 USD for stage III and 63,697.33 USD for stage IV. We also observed that DC per patient-year increased according to clinical stage. In the first year, average cost was 15,183.85 USD for stage I, while it was 44,160.74 USD for stage IV. Those DC decreased along the years in all stages. For example, in the seventh year of follow-up, the average DC was only US$ 467.27 for stage I (2005 purchasing power parity index 1 USD = 1.4 BRL). The 5-year overall survival and progression free survival were 100% and 100% for stage I, 92.2% and 91.9% for stage II, 87.5% and 82.1% for stage III, and 60% and 60% for stage IV, respectively. CONCLUSIONS: Breast cancer accounts for a significant part of the health insurance budget. Later stage at diagnosis is associated with higher DC per patient-year of treatment, and lower probability of 5-year survival.
PCN41 HEALTH CARE COST OF BREAST CANCER: A CLAIMS DATA ANALYSIS
Fu AZ 1 , Chen L 2 , Christiansen NP 3 , Sullivan SD 4 1 Cleveland Clinic, Cleveland, OH, USA, 2 Sanofi-Aventis, Bridgewater, NJ, USA, 3 Medical University of South Carolina, Charleston, SC, USA, 4 University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA OBJECTIVES: There is a paucity of updated literature on the total direct costs of breast cancer (BC) from a US managed care perspective. This study was conducted to analyze the economic burden of BC with a focus on direct health care cost in the US. METHODS: This was a retrospective matched cohort study using a large claims database from a US national commercially-insured population (January 1, 2003 -September 30, 2008 . Women aged ≥18 were selected with ≥2 BC diagnoses on different dates within 90 days. The date of the first BC diagnosis was the index date for case cohort. The control cohort (without BC diagnosis) was selected with a 3:1 ratio by matching to the cases based on index date (same year and month), age (5-year range), region, employer, and health insurance type. Both cohorts were required to have continuous enrollment for at least 6-months prior to and 12-months after the index date. Generalized linear model (GLM) was applied to evaluate the 1-year post-index cost difference between cases and controls with adjustment of demographics, comorbid conditions, and pre-index total health care cost. RESULTS: Based on the selection criteria, 140,228 patients were included with mean (SD) age of 52.1 (7.5) years. The total 1-year health care costs for cases and controls were $61,167 and $6,296, respectively (p < 0.001). GLM predicted that the adjusted incremental health care cost was $42,401 (p < 0.001) per BC patient per year, which included 12%, 86%, and 2% for inpatient, outpatient, and prescription use. CONCLUSIONS: This study demonstrated that breast cancer is an expensive disease condition, which consumes on average $40,000 more per patient within the first year of diagnosis for the US health care system. Most of the direct health care cost is spent in outpatient care settings.
PCN42 INDIRECT COST ASSOCIATED WITH BREAST CANCER TO US EMPLOYERS
Fu AZ 1 , Chen L 2 , Christiansen NP 3 , Sullivan SD 4 1 Cleveland Clinic, Cleveland, OH, USA, 2 Sanofi-Aventis, Bridgewater, NJ, USA, 3 Medical University of South Carolina, Charleston, SC, USA, 4 University of Washington, Seattle, WA, USA OBJECTIVES: Few data exist on the impact of breast cancer (BC) on absenteeism and short-term disability (STD) to employers. This study was undertaken to estimate BC related indirect cost impacts within the US population. METHODS: This was a retrospective matched cohort study using a large health care claims database from a US national commercially-insured population (2003) (2004) (2005) (2006) (2007) . Women aged ≥18 were selected with ≥2 BC diagnoses on different dates within 90 days. The date of the first BC diagnosis was the index date for case cohort. The control cohort (without BC diagnosis) was selected with 1:1 matching to cases based on index date (same year and month), age (5 year range), region, employer, and health insurance type. Continuous enrollment for at least 6-months prior to and 12-months after the index date was required for both cohorts. Indirect cost was measured by days of absenteeism and STD, multiplied by age-matched average wage rates from Bureau of Labor Statistics. Two-part model was used to assess the 1-year post-index indirect cost difference between cases and controls with the adjustment of demographics, comorbid conditions, and pre-index total health care cost. RESULTS: Based on the inclusion criteria, 856 and 2668 patients were selected for absenteeism and STD outcomes, respectively. Costs of absenteeism were $4972 and $2937, and costs of STD were $7199 and $653 for cases and controls, respectively, within the post-index year (both p < 0.001). Twopart models predicted that the adjusted incremental costs for absenteeism and STD were $1911 and $6157 (p < 0.001) per BC patient per year. CONCLUSIONS: This study demonstrated that breast cancer is associated with approximately $8000 more in indirect cost per patient to the employer within the first year of diagnosis.
PCN43 INITIAL COSTS OF TREATMENT AMONG STAGE IV PROSTATE CANCER (PCA) CHEMOTHERAPY PATIENTS IN SEER-MEDICARE
Onukwugha E, Mullins CD 1 , Seal B 2 , Hussain A 3 1 University of Maryland School of Pharmacy, Baltimore, MD, USA, 2 Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, USA, 3 University of Maryland School of Medicine, Baltimore, MD, USA OBJECTIVES: Little is known about how resource utilization in the initial treatment period among advanced stage PCa patients differs between those receiving versus those not receiving chemotherapy, even for docetaxel, the earliest approved agent for metastatic disease. METHODS: We analyzed patients aged 66 or older from the linked Surveillance, Epidemiology, and End Results & Medicare (SEER-Medicare) database. Patients were diagnosed with PCa between 2000 and 2005 and were followed until censoring. We restricted the cohort to patients with incident Stage IV disease (AJCC-TNM classification) and at least 24 months of post-diagnosis follow-up data. Initial costs (Medicare payments) were defined as costs incurred from 2 months before diagnosis to 12 months post-diagnosis and patients were stratified according to whether they received chemotherapy, and subsequently, whether they received docetaxel. RESULTS: Application of the inclusion criteria resulted in 4,088 Stage IV PCa patients, of which 23% (N = 933) reported chemotherapy. Among chemotherapy users, 63% (N = 592) received docetaxel-containing regimens. Initial costs totaled $78.3M while PCa-specific initial costs totaled $49.9M. For the full sample (F), chemotherapy subsample (C), and no chemotherapy subsample (NC), the proportions of total costs attributed to PCa-specific inpatient costs (IC), non-PCa-specific IC, PCa-specific outpatient costs (OC), non-PCa-specific OC, and other costs were distributed as follows: 
RESULTS:
The study identified 407 MM and 13,796 non-MM patients (mean age 48.8 and 47.8 years, respectively). For the MM patients, PPPM utilization increased 3 to 12 times from the pre-metastatic period (inpatient: 0.007 to 0.090, emergency room: 0.010 to 0.044, office: 0.724 to 2.592, all with p < 0.0001, and hospital outpatient: 0.226 to 1.029, p = 0.0442), while the PPPM total cost increased 7 times ($803.2 to $5,439.9, p < 0.0001). For the non-MM patients, utilization increased marginally following melanoma diagnosis (inpatient: 0.005 to 0.008, emergency room: 0.012 to 0.016, office: 0.696 to 1.214, and hospital outpatient: 0.136 to 0.291, all p < 0.0001). The total cost for non-MM patients doubled following diagnosis of melanoma ($432.3 to $955.2, p < 0.0001). Upon metastasis, the disease attributed cost increased 9 times ($523 to $4638). CONCLUSIONS: The cost burden from resource utilization increases substantially with metastasis of melanoma. Treatments that significantly delay disease progression in these patients will reduce this burden.
PCN45 HEALTH CARE RESOURCE UTILIZATION (HRU) IN ADVANCED OVARIAN CANCER-FINDINGS FROM LINKED SEER-MEDICARE DATA
Parthan A 1 , Gao SK 2 , Song R 3 , Borker R 2 , Langeberg WJ 2 , Teitelbaum A 3 , Oglesby A 2 1 i3 Innovus, San Francisco, CA, USA, 2 Amgen, Inc., Thousand Oaks, CA, USA, 3 i3 Innovus, Eden Prairie, MN, USA OBJECTIVES: To estimate the health care costs, treatment patterns, and health care resource use in advanced ovarian cancer (aOC) patients receiving first line chemotherapy. METHODS: Incident aOC patients between 2000-2005 were identified from the linked Surveillance, Epidemiology and End-Results (SEER)/Medicare data file using an ICD-9 code 56.9 with a "distant" tumor in the SEER staging variable. Women ≥65 years at the time of aOC diagnosis (i.e. index date), with at least three months of data preceding the initial diagnosis were included. Subjects were followed from 30 days prior to index date until the first occurrence of the following: receipt of a 2 nd line treatment given after a minimum of 90 days treatment free interval, death or the end of the Medicare claims data (i.e., December 2007). Measures of overall HRU included hospitalizations, outpatient visits, physician visits, hospice care, home health care, and skilled nursing facility utilization. Costs of each HRU event were estimated by summing all Medicare payments, primary insurer payments, patient copayments and deductibles for services in the claims files. Average health care costs per event per patient (e.g. hospitalization) are calculated as total cost per event divided by number of patients with the event. RESULTS: A total of 3895 aOC subjects receiving first-line chemotherapy were included in the analysis. Mean age was 75 years. Carboplatin+paclitaxel (73%), carboplatin alone (8.5%), and carboplatin+docetaxel (7%) were the three most commonly used 1 st line chemotherapeutic agents. The mean 1 st line treatment duration was 128 days (SD 95.8). The rate of hospitalization was 1.5 per person-year. Mean hospitalization cost per patient was $12,997 (SD $10,499). Mean SNF and Hospice Care costs per patient were $7,509 (SD $7,171) and $7,025 (SD $11,370) respectively. CONCLUSIONS: Carboplatin-paclitxel combination was the most commonly used first line chemotherapeutic regimen. In aOC patients, hospitalization costs were substantial in women with aOC receiving 1st line chemotherapy.
